Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin in young adults with Autism Spectrum Disorder
2013-003067-59Phase 2Active
- Sponsor
- Azienda Ospedaliera G. Brotzu
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Azienda Ospedaliera G. Brotzu. Primary endpoints: Safety and tolerability of intranasal oxytocin and Social cognition (acute effects). Started Jun 2021; status: active.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2013-003067-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003067-59.